DRR168584
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.320
- P53_PATHWAY+0.310
- ESTROGEN_RESPONSE_EARLY+0.290
- ESTROGEN_RESPONSE_LATE+0.270
- ANGIOGENESIS+0.260
- COAGULATION+0.260
- XENOBIOTIC_METABOLISM+0.260
- MYC_TARGETS_V2+0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.240
- ADIPOGENESIS+0.230
Top 10 suppressed
- G2M_CHECKPOINT-0.490
- E2F_TARGETS-0.430
- MITOTIC_SPINDLE-0.390
- PROTEIN_SECRETION-0.390
- ANDROGEN_RESPONSE-0.320
- PI3K_AKT_MTOR_SIGNALING-0.240
- UV_RESPONSE_DN-0.240
- MTORC1_SIGNALING-0.230
- UNFOLDED_PROTEIN_RESPONSE-0.210
- WNT_BETA_CATENIN_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303751 | — | — | 0.829 |
| 2 | TCGA-LL-A9Q3-01A-11R-A41B-07 | — | B | 0.787 |
| 3 | MBCProject_0988_T1_RNA | — | B | 0.782 |
| 4 | SRR25043613 | — | — | 0.775 |
| 5 | TCGA-LL-A6FQ-01A-11R-A31O-07 | — | B | 0.760 |
| 6 | TCGA-V7-A7HQ-01A-11R-A33J-07 | — | B | 0.752 |
| 7 | TCGA-AC-A3QP-01A-11R-A22U-07 | — | B | 0.750 |
| 8 | 9c8140ab-454c-4f62-aa6e-d1cfe4e498e0 | — | — | 0.747 |
| 9 | TCGA-B6-A0I5-01A-11R-A034-07 | — | B | 0.746 |
| 10 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |